When setting the price of an individual medicine, companies will consider a number of factors including how well the medicine treats patients, how many patients might benefit from it, the value that health systems might place on a medicine in the disease area in question and the price of competing products.
There are a number of ways in which medicines costs are managed, with the UK regarded as having one of the world’s most rigorous systems.
NICE – the National Institute for Health and Care Excellence - is the body which advises the NHS on whether a new medicine is cost effective; It does this by comparing how much it costs to give a patient an extra year of ‘quality life’ compared with the treatment already being used.
If the new treatment is deemed to be too expensive compared with the benefits it brings it is not recommended for use.
Companies need to take into account the costs of research and development – not just for the successful medicine but also for the many which have failed.
Our industry constantly works with NICE to make sure that their assessments remain fit for purpose across all disease areas to ensure transparency, clarity and fairness for all patients throughout the UK.
We want to make sure that patients in Scotland can continue to access the latest new medicines. It is not only about protecting the checks and balances we have in place today but making sure Scotland is ready for the future.
There’s more that can be done to speed up R&D of new medicines: including making the most of the health data that’s collected by NHS Scotland. If we are serious about greater efficiency, then it is important to use the data we have.
We’re proud to be delivering for the health and the economy of Scotland. The pharmaceutical industry delivers £2.7 billion into the Scottish economy – that equates to 5,000 jobs which go on to support thousands more in the communities the length and breadth of Scotland.